María Natalia Gandur Quiroga: Disappointing update from ESMO 23: Christina Gratzke reveals KEYNOTE-991 study results.
Quoting María Natalia Gandur Quiroga on X/Twitter:
“Disappointing update from ESMO 23: Christina Gratzke reveals KEYNOTE-991 study results, emphasising the complexities of treating metastatic hormone-sensitive prostate cancer (mHSPC). Here’s what we’ve learned:
KEYNOTE-991 Study Insights:
– Study halted: Pembro + Enza + ADT didn’t improve outcomes in mHSPC patients, escalating risks instead.
– rPFS, OS, and TT SSE outcomes were comparable between Pembro + Enza vs PBO + Enza groups.
– Significant increase in Grade ≥3 Treatment-Related Adverse Events (TRAEs) observed with the combination therapy .
This setback highlights the challenges in prostate cancer research and underscores the importance of rigorous evaluation in clinical trials. Research continues for better solutions in the fight against mHSPC.”
Source: María Natalia Gandur Quirog/Twitter.
María Natalia Gandur Quiroga is a Medical Oncologist and Chief of the Division of Genitourinary Medical Oncology at the Instituto de Oncología Ángel H. Roffo in Buenos Aires, Argentina. She is a Professor of Medicine at the University of Buenos Aires at the Oncologists Post Graduates Studies. Her research focuses on clinical trials with aims to improve the treatment of patients with urologic tumors. She is an active member of the European Association for Cancer Research, Argentinian Medical Association and American Society of Clinical Oncology.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023